semaj83/ctmatch_classification huggingface dataset:
Patient description: Karen is a 72-year-old woman with hypertension and type 2 diabetes, who was hospitalized for cryptogenic stroke two weeks ago. At the time, computed tomography was negative for brain hemorrhage and she was given thrombolytic therapy with resolution of her symptoms. Transesophageal echocardiogram and magnetic resonance angiogram of brain and great vessels found no evidence of abnormalities. She presents currently with a blood pressure of 120/70 mm Hg, normal glucose, and normal sinus rhythm on a 12-lead electrocardiogram. She reports history of occasional palpitations, shortness of breath and chest pain lasting for a few minutes and then stopping on their own.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Hemodialysis Hyperphosphatemia hemodialysis patients with hyperphosphatemia who require phosphate binders hemodialysis for more than 3 months patients who have at least one calcification risk factor (elderly > 65 years, postmenopausal woman, type 2 diabetes mellitus) intact-PTH > or = 240pg/mL life expectancy > 1 year with written informed consent  contraindications to lanthanum carbonate and calcium carbonate swallowing disorders severe GI disorders history of obstructed bowels history of IHD/stroke within 6 months before randomization NYHA classification Ⅲ-Ⅳ severe liver dysfunction (AST or ALT greater than 3 times the upper limit of institution require treatment of arrhythmia severe malnutrition malignancy of any type within the last five years
Patient description: Karen is a 72-year-old woman with hypertension and type 2 diabetes, who was hospitalized for cryptogenic stroke two weeks ago. At the time, computed tomography was negative for brain hemorrhage and she was given thrombolytic therapy with resolution of her symptoms. Transesophageal echocardiogram and magnetic resonance angiogram of brain and great vessels found no evidence of abnormalities. She presents currently with a blood pressure of 120/70 mm Hg, normal glucose, and normal sinus rhythm on a 12-lead electrocardiogram. She reports history of occasional palpitations, shortness of breath and chest pain lasting for a few minutes and then stopping on their own.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Atrial Fibrillation atrial fibrillation scheduled for catheter ablation  contraindication to magnetic resonance imaging pregnancy life expectancy of less than six months participation in another trial that would conflict with this trial
Patient description: Karen is a 72-year-old woman with hypertension and type 2 diabetes, who was hospitalized for cryptogenic stroke two weeks ago. At the time, computed tomography was negative for brain hemorrhage and she was given thrombolytic therapy with resolution of her symptoms. Transesophageal echocardiogram and magnetic resonance angiogram of brain and great vessels found no evidence of abnormalities. She presents currently with a blood pressure of 120/70 mm Hg, normal glucose, and normal sinus rhythm on a 12-lead electrocardiogram. She reports history of occasional palpitations, shortness of breath and chest pain lasting for a few minutes and then stopping on their own.

Clinical trial eligibility criteria: eligible ages (years): 35.0-999.0,  Acute Coronary Syndrome Coronary Artery Disease Cardiac Death Myocardial Infarction Patient is in Sinus Rhythm Typical or atypical chest pain lasting more than 5 min in the last 24 hs Estimated pre-test probability of significant coronary artery disease more than 15% Absence of ECG changes suggestive of myocardial ischemia (ST-segment deviation >1 mm or T Wave inversion > 4 mm in at least two contiguous leads) Negative initial troponins I at admission (<0.05 ng/ml)  Known allergy to iodinated contrast Known renal insufficiency or Creatinine >1.5 mg/dl at admission History of known coronary artery disease or prior myocardial revascularization Any of the following:hemodynamic instability, persistent chest pain despite treatment, Systolic blood pressure <100 mm Hg Cardiac arrhythmia with rapid or irregular ventricular response Inability to perform an exercise test Patient is incapable of providing informed consent
Patient description: Karen is a 72-year-old woman with hypertension and type 2 diabetes, who was hospitalized for cryptogenic stroke two weeks ago. At the time, computed tomography was negative for brain hemorrhage and she was given thrombolytic therapy with resolution of her symptoms. Transesophageal echocardiogram and magnetic resonance angiogram of brain and great vessels found no evidence of abnormalities. She presents currently with a blood pressure of 120/70 mm Hg, normal glucose, and normal sinus rhythm on a 12-lead electrocardiogram. She reports history of occasional palpitations, shortness of breath and chest pain lasting for a few minutes and then stopping on their own.

Clinical trial eligibility criteria: eligible ages (years): 35.0-85.0,  Hypertension Stroke aged 35 to 85 years hypertensive patients who had an ischemic stroke  patients aged below 35 years or above 86 years patients who had a hemorrhagic stroke patients whose systolic BP (SBP) was over 220 mmHg or whose diastolic BP (DBP) was above 120 mmHg during an acute phase, or whose SBP was over 180 mmHg or whose DBP was over 110 mmHg one week after their hospital visit patients with secondary hypertension related to renovascular, endocrinologic, or pregnant conditions patients who went to bed in the middle of the day or very late at night; (6) patients who were using intravenous antico-agulants or thrombolytics (7) patients with a severe stroke (NIH stroke scale > 20); (8) patients who could not give their consent to investigators; (9) patients with severely impaired liver function (AST or ALT ≥ 100); (10) patients with severely impaired renal function (serum creatinine ≥ 2.0 mg/dL); (11) patients with cancer; (12) patients who were pregnant or lactating; (13) patients with other grave diseases such as hypertensive encephalopathy, aortic dissection, acute myocardial infarction, or severe congestive heart failure; and (14) patients who were allergic to the test or control drugs
Patient description: Karen is a 72-year-old woman with hypertension and type 2 diabetes, who was hospitalized for cryptogenic stroke two weeks ago. At the time, computed tomography was negative for brain hemorrhage and she was given thrombolytic therapy with resolution of her symptoms. Transesophageal echocardiogram and magnetic resonance angiogram of brain and great vessels found no evidence of abnormalities. She presents currently with a blood pressure of 120/70 mm Hg, normal glucose, and normal sinus rhythm on a 12-lead electrocardiogram. She reports history of occasional palpitations, shortness of breath and chest pain lasting for a few minutes and then stopping on their own.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Atrial Fibrillation Atrial Flutter Patient meets the approved FDA indication to receive the ICM Patient is suspected, based on demographics, to be at high risk of having AF, as determined by the clinical investigator Patient has a CHA2DS2-VASc score ≥ 2 [Note: stroke/TIA criterion as part of the CHA2DS2-VASc score for this trial is limited to either an ischemic stroke or TIA, which occurred more than one year prior to enrollment.] Patient is 18 years of age or older Patient has a life expectancy of 18 months or more  Patient has a documented history of AF or atrial flutter Patient has a symptom complex consistent with an arrhythmia (where an ICM may have an alternate indication for use) Patient had an ischemic stroke or TIA within past year prior to enrollment Patient has a history of a hemorrhagic stroke Patient is currently implanted with a permanent pacemaker, insertable loop recorder, implantable defibrillator, cardiac resynchronization therapy device (pacemaker or defibrillator) NYHA Class IV Heart Failure patient Patient had heart surgery within previous 90 days prior to enrollment Patient had an MI within the previous 90 days prior to enrollment Patient is taking chronic immunosuppressant therapy Patient is taking an anti-arrhythmic drug
Patient description: Karen is a 72-year-old woman with hypertension and type 2 diabetes, who was hospitalized for cryptogenic stroke two weeks ago. At the time, computed tomography was negative for brain hemorrhage and she was given thrombolytic therapy with resolution of her symptoms. Transesophageal echocardiogram and magnetic resonance angiogram of brain and great vessels found no evidence of abnormalities. She presents currently with a blood pressure of 120/70 mm Hg, normal glucose, and normal sinus rhythm on a 12-lead electrocardiogram. She reports history of occasional palpitations, shortness of breath and chest pain lasting for a few minutes and then stopping on their own.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Paroxysmal Atrial Fibrillation paroxysmal atrial fibrillation, symptomatic  atrial fibrillation other than PAF, asymptomatic, previous AF ablation
Patient description: Karen is a 72-year-old woman with hypertension and type 2 diabetes, who was hospitalized for cryptogenic stroke two weeks ago. At the time, computed tomography was negative for brain hemorrhage and she was given thrombolytic therapy with resolution of her symptoms. Transesophageal echocardiogram and magnetic resonance angiogram of brain and great vessels found no evidence of abnormalities. She presents currently with a blood pressure of 120/70 mm Hg, normal glucose, and normal sinus rhythm on a 12-lead electrocardiogram. She reports history of occasional palpitations, shortness of breath and chest pain lasting for a few minutes and then stopping on their own.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Atrial Fibrillation Age >= 18 years CHADS2 score >=2 Sinus rhythm Cardiac Implantable Electronic Device  Atrial fibrillation Severe heart valve disease Anticoagulation therapy Pregnancy
Patient description: Karen is a 72-year-old woman with hypertension and type 2 diabetes, who was hospitalized for cryptogenic stroke two weeks ago. At the time, computed tomography was negative for brain hemorrhage and she was given thrombolytic therapy with resolution of her symptoms. Transesophageal echocardiogram and magnetic resonance angiogram of brain and great vessels found no evidence of abnormalities. She presents currently with a blood pressure of 120/70 mm Hg, normal glucose, and normal sinus rhythm on a 12-lead electrocardiogram. She reports history of occasional palpitations, shortness of breath and chest pain lasting for a few minutes and then stopping on their own.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Ischemic Stroke Atrial Fibrillation Transient Ischemic Attacks Transient Cerebrovascular Events Patients >18 years of age Signs and symptoms suggestive of acute ischemic stroke or TIA Arrival to the emergency department or hospital within 8 hrs of symptom onset or last known normal time Head CT or MRI ruling out other pathology such as vascular malformation, hemorrhage, tumor or abscess which would likely be responsible for presenting neurologic symptoms Consent must be obtained  Any central nervous system infection, i.e. meningitis or encephalitis in the past 30 days Any form of head trauma, stroke or intracranial hemorrhage in the past 30 days Known primary or metastatic cancer involving the brain Active Cancer defined as a diagnosis of cancer, within 6 months before enrollment, any treatment for cancer within the previous 6 months, or recurrent or metastatic cancer Autoimmune diseases: such as lupus, rheumatoid arthritis, Crohn's disease, ulcerative colitis Active infectious diseases (eg. HIV/AIDS, hepatitis C) Any underlying medical condition which in the opinion of the investigator would prohibit the patient from providing informed consent Major surgery within three months prior to the index event
Patient description: Karen is a 72-year-old woman with hypertension and type 2 diabetes, who was hospitalized for cryptogenic stroke two weeks ago. At the time, computed tomography was negative for brain hemorrhage and she was given thrombolytic therapy with resolution of her symptoms. Transesophageal echocardiogram and magnetic resonance angiogram of brain and great vessels found no evidence of abnormalities. She presents currently with a blood pressure of 120/70 mm Hg, normal glucose, and normal sinus rhythm on a 12-lead electrocardiogram. She reports history of occasional palpitations, shortness of breath and chest pain lasting for a few minutes and then stopping on their own.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Blood Pressure Depression Panic Attack Fibromyalgia POTS Inappropriate Sinus Tachycardia Coronary Heart Disease Acute Coronary Syndrome (ACS) Acute Myocardial Infarction (AMI) Cerebrovascular Disease (CVD) Transient Ischemic Attack (TIA) Atrial Fibrillation Diabetes Mellitus Cancer Systolic Heart Failure Diastolic Heart Failure Chronic Fatigue Syndrome Syncope Vasovagal Syncope Any patient regardless of the age of gender  Any non-correctable secondary cause of increase or decrease in blood pressure or a pathology that alters the prognosis before the entrance of the patient into this registry nephropathy prior to the admission familial dyslipidemia previous gastric bypass pre-existing heart failure chemotherapy-induced cardiotoxicity arrhythmogenic right ventricular dysplasia long QT syndrome hypertrophic cardiomyopathy
Patient description: Karen is a 72-year-old woman with hypertension and type 2 diabetes, who was hospitalized for cryptogenic stroke two weeks ago. At the time, computed tomography was negative for brain hemorrhage and she was given thrombolytic therapy with resolution of her symptoms. Transesophageal echocardiogram and magnetic resonance angiogram of brain and great vessels found no evidence of abnormalities. She presents currently with a blood pressure of 120/70 mm Hg, normal glucose, and normal sinus rhythm on a 12-lead electrocardiogram. She reports history of occasional palpitations, shortness of breath and chest pain lasting for a few minutes and then stopping on their own.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Pulmonary Embolism Patients with massive PE aged 18 years or older with confirmed PE and able to give informed consent will be included in the study. PE is defined according to current guidelines as adult patients presenting with signs and symptoms suggestive of PE plus imaging documentation on computed tomography angiography. Massive PE was defined as acute PE with sustained hypotension (systolic blood pressure<90 mm Hg for at least 15 minutes or requiring inotropic support, not due to a cause other than PE, such as arrhythmia, hypovolemia, sepsis, or left ventricular [LV] dysfunction), pulselessness, or persistent profound bradycardia (heart rate<40 bpm with signs or symptoms of shock)  Patients with prior intracranial hemorrhage, known structural intracranial cerebrovascular disease (eg, arteriovenous malformation), known malignant intracranial neoplasm, ischemic stroke within 3 months, suspected aortic dissection, active bleeding or bleeding diathesis, recent surgery encroaching on the spinal canal or brain, and recent significant closed-head or facial trauma with radiographic evidence of bony fracture or brain injury were excluded from the study
Patient description: Karen is a 72-year-old woman with hypertension and type 2 diabetes, who was hospitalized for cryptogenic stroke two weeks ago. At the time, computed tomography was negative for brain hemorrhage and she was given thrombolytic therapy with resolution of her symptoms. Transesophageal echocardiogram and magnetic resonance angiogram of brain and great vessels found no evidence of abnormalities. She presents currently with a blood pressure of 120/70 mm Hg, normal glucose, and normal sinus rhythm on a 12-lead electrocardiogram. She reports history of occasional palpitations, shortness of breath and chest pain lasting for a few minutes and then stopping on their own.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Permanent Atrial Fibrillation To be eligible, each patient must be in the following condition Permanent atrial fibrillation (>6 months) which has been considered unsuitable for ablation or failed ablation Narrow QRS ≤ 110 ms Severely symptomatic (atrial fibrillation-related symptoms), refractory to drug therapy for rate control At least one hospitalization related to atrial fibrillation and/or heart failure in the previous year (see definition below)  New York Heart Association (NYHA) class IV and systolic blood pressure <80 mmHg despite optimized therapy severe concomitant non-cardiac disease need for surgical intervention myocardial infarction within the previous 3 months previous implanted devices (PM/ICD/CRT)
Patient description: Karen is a 72-year-old woman with hypertension and type 2 diabetes, who was hospitalized for cryptogenic stroke two weeks ago. At the time, computed tomography was negative for brain hemorrhage and she was given thrombolytic therapy with resolution of her symptoms. Transesophageal echocardiogram and magnetic resonance angiogram of brain and great vessels found no evidence of abnormalities. She presents currently with a blood pressure of 120/70 mm Hg, normal glucose, and normal sinus rhythm on a 12-lead electrocardiogram. She reports history of occasional palpitations, shortness of breath and chest pain lasting for a few minutes and then stopping on their own.

Clinical trial eligibility criteria: eligible ages (years): 60.0-999.0,  Transient Arthropathy of Hip y/o/ and more Both sexes Schedule for total hip replacement  Patient with previous bedsore Patients under 60 y.0 Previous CVA
Patient description: Karen is a 72-year-old woman with hypertension and type 2 diabetes, who was hospitalized for cryptogenic stroke two weeks ago. At the time, computed tomography was negative for brain hemorrhage and she was given thrombolytic therapy with resolution of her symptoms. Transesophageal echocardiogram and magnetic resonance angiogram of brain and great vessels found no evidence of abnormalities. She presents currently with a blood pressure of 120/70 mm Hg, normal glucose, and normal sinus rhythm on a 12-lead electrocardiogram. She reports history of occasional palpitations, shortness of breath and chest pain lasting for a few minutes and then stopping on their own.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Acute Ischaemic Stroke or less years old patients with acute stroke produced by a main artery occlusion NIHSS National Institutes of Health Stroke Scale score greater than 6 (severe neurological impairment) Patients receiving EVT or IVT within 4.5 hours after onset  EVT or IVT contraindication Previous neurological impairment, severe concomitant disease or poor prognosis Pregnancy or breastfeeding Known hypersensitivity to any study drugs Severe organic disease for which there is not risk compensation
Patient description: Karen is a 72-year-old woman with hypertension and type 2 diabetes, who was hospitalized for cryptogenic stroke two weeks ago. At the time, computed tomography was negative for brain hemorrhage and she was given thrombolytic therapy with resolution of her symptoms. Transesophageal echocardiogram and magnetic resonance angiogram of brain and great vessels found no evidence of abnormalities. She presents currently with a blood pressure of 120/70 mm Hg, normal glucose, and normal sinus rhythm on a 12-lead electrocardiogram. She reports history of occasional palpitations, shortness of breath and chest pain lasting for a few minutes and then stopping on their own.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Stroke Atrial Fibrillation Premature Atrial Complexes admitted with ischemic stroke at a single center time from diagnose to maximum 7 days written informed consent or surrogate informed consent eligible age > 18 years  hemorrhagic stroke terminal illness and expected lifespan of less than 6 months any physical or mental condition which make the patients unsuitable for participation in the study known with a pacemaker anticoagulation treatment of other reasons than atrial fibrillation
Patient description: Karen is a 72-year-old woman with hypertension and type 2 diabetes, who was hospitalized for cryptogenic stroke two weeks ago. At the time, computed tomography was negative for brain hemorrhage and she was given thrombolytic therapy with resolution of her symptoms. Transesophageal echocardiogram and magnetic resonance angiogram of brain and great vessels found no evidence of abnormalities. She presents currently with a blood pressure of 120/70 mm Hg, normal glucose, and normal sinus rhythm on a 12-lead electrocardiogram. She reports history of occasional palpitations, shortness of breath and chest pain lasting for a few minutes and then stopping on their own.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cryptogenic Embolic Stroke Active Cancer Subjects with acute ischemic stroke who presented within 7 days from symptom onset Subjects with unknown cause of stroke despite of initial evaluation including electrocardiogram and brain imaging upon admission Subjects who performed brain magnetic resonance image (MRI) and MR angiography (MRA), cardiac work-ups (12-lead electrocardiography, transthoracic and/or transesophageal echocardiography with injection of agitated saline (or agitated saline transcranial Doppler monitoring), and 24-hour Holter and/or telemonitoring) Subjects with informed consent  Subjects with single subcortical infarction Subjects with primary brain tumor
Patient description: Karen is a 72-year-old woman with hypertension and type 2 diabetes, who was hospitalized for cryptogenic stroke two weeks ago. At the time, computed tomography was negative for brain hemorrhage and she was given thrombolytic therapy with resolution of her symptoms. Transesophageal echocardiogram and magnetic resonance angiogram of brain and great vessels found no evidence of abnormalities. She presents currently with a blood pressure of 120/70 mm Hg, normal glucose, and normal sinus rhythm on a 12-lead electrocardiogram. She reports history of occasional palpitations, shortness of breath and chest pain lasting for a few minutes and then stopping on their own.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Stroke Female or male in-patient Age 18 years Clinical diagnosis of ischemic stroke causing a measurable neurological deficit defined as impairment of language, motor function, cognition, gaze, vision and/or neglect. Ischemic stroke is defined as an event characterized by sudden onset of acute focal neurological deficit, presumed to be caused by cerebral ischemia, after CT scan of hemorrhage Onset of symptoms within 3 hours prior to initiation of thrombolysis treatment Stroke symptoms present for at least 30 minutes that had not significantly improved before treatment. Symptoms must be distinguishable from an episode of generalized ischemia (i.e. syncope), seizure, or migraine disorder Patients are willing to receive thrombolysis treatment and to give informed consent with regard to retrieval of data and follow up procedures, according to the regulations in participating countries Willingness and ability to comply with the study protocol  Evidence of intracranial hemorrhage (ICH) on the CT-scan Symptoms of ischemic attack began more than 3 hours prior to infusion start or when time of symptom onset is unknown Minor neurological deficit or symptoms rapidly improving before start of infusion Severe stroke as assessed clinically and/or by appropriate imaging techniques Seizure at onset of stroke Symptoms suggestive of subarachnoid hemorrhage, even if the CT-scan is normal Administration of heparin within the previous 48 hours and a thromboplastin time exceeding the upper limit of normal for laboratory Patients with any history of prior stroke and concomitant diabetes Prior stroke within the last 3 months Platelet count of below 100,000/mm³